Alle Studien
RekrutierungPHASE4INTERVENTIONELL

Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients

This research trial, called TripleTRE, is looking at the best way to start treatment for people with a condition called pulmonary arterial hypertension (PAH), which causes high blood pressure in the lungs. It compares two different treatment approaches for adult patients who are newly diagnosed or haven't been treated for PAH before. One group receives a combination of three medicines: two oral tablets and one medicine (treprostinil) given by injection. The other group receives two oral tablets, which is a common starting treatment. The main goal is to see which treatment helps more patients achieve a 'low risk' status, meaning their condition is better managed. This study will help doctors improve care for PAH patients.

Auf einen Blick

Status
Rekrutierung
Phase
PHASE4
Sponsor
AOP Orphan Pharmaceuticals AG
Einschreibeziel
110
Starten
06 Dec 2023
Geschätzte Fertigstellung
30. Juni 2027

Worum geht es in dieser Studie?

Pulmonary arterial hypertension, or PAH, is a serious condition where the blood pressure in the arteries leading to your lungs becomes too high. This makes your heart work much harder and can lead to serious health problems. Doctors are always looking for the best ways to treat PAH and help patients live better lives. This study, called TripleTRE, is exploring whether starting treatment with a combination of three medicines might be more effective than starting with two for certain patients.

Currently, many patients with PAH start treatment with two oral medicines. These medicines work in different ways to relax blood vessels in the lungs and lower blood pressure. TripleTRE is investigating whether adding a third medicine, treprostinil (which is given by injection), right from the start can lead to better outcomes, especially for patients with a higher risk level or more severe symptoms.

This trial is for adults with specific types of PAH who are newly diagnosed or haven't received PAH treatment in the past three months. Researchers will carefully monitor how patients respond to their assigned treatment over several months to understand the safety and effectiveness of each approach. The results could help doctors decide the best way to begin treatment for future PAH patients.

Wichtige Erkenntnisse

  • Compares two starting treatments for PAH: two pills vs. two pills plus an injected medicine.
  • Aims to find out which approach leads to better health for PAH patients.
  • Involves adults (18-70) with specific types of newly diagnosed or untreated PAH.
  • Participation lasts between 6 months and a year with regular hospital visits.
  • You will know which treatment you are receiving (it's 'open-label').

Wer könnte berechtigt sein?

This study is looking for adults aged between 18 and 70 years old who have just been diagnosed with certain types of pulmonary arterial hypertension (PAH) or haven't been treated for it in the last three months. These types include PAH that doesn't have a clear cause (idiopathic), PAH that runs in families (hereditary), PAH caused by medicines or toxins, PAH linked to connective tissue diseases, or PAH with a repaired heart defect from birth.

You might be able to join if your PAH is considered 'intermediate-high risk' or 'intermediate-low risk' but with some severe signs of how your heart and lungs are working. Doctors will do some tests, including a special heart catheterisation, to check your heart and lung pressures and confirm your diagnosis.

However, you won't be able to join if you have certain other types of PAH (like those linked to schistosomiasis, HIV, liver problems, or a widespread skin condition called diffuse systemic sclerosis) or if your heart defect from birth hasn't been fixed. You also can't participate if you've already had PAH-specific treatment recently, if your PAH responds to certain tablets called calcium channel blockers, or if you have certain other lung or heart conditions.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Are you between 18 and 70 years old?
  2. Have you been diagnosed with PAH recently, or have you not taken PAH medicines in the last 3 months?
  3. Is your PAH one of these types: idiopathic, hereditary, drug/toxin-induced, associated with connective tissue disease, or with corrected congenital heart disease?
  4. Are you able to use reliable contraception if you're a woman who could become pregnant?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part in the TripleTRE study, you'll be randomly assigned to one of two treatment groups, like flipping a coin. You'll receive either two oral medications or the same two oral medications along with treprostinil, which is given by an injection. All medicines will be started within three weeks of joining the study. You'll have regular visits to the hospital for check-ups, tests, and to monitor how you're feeling and how the treatment is working. This will include blood tests, heart and lung function tests, and possibly repeats of the heart catheterisation. The study will follow your progress for about 24 to 48 weeks, which is roughly between six months and a year.

Potenzielle Risiken und Vorteile

Participating in a study like TripleTRE means you'll receive close medical attention and access to potentially effective treatments for your PAH. While the goal is to find better treatments, there's no guarantee that the treatment you receive will improve your condition, and side effects are possible with any medication. The additional treprostinil in one group is given by injection, which has its own potential risks like injection site reactions. The research team will explain all known risks of the medicines used. You have the right to leave the study at any time, for any reason, without it affecting your usual medical care.

Locations (19)

  • Ordensklinikum Linz
    Verifizierte Postleitzahl
    Linz, Österreich· Rekrutierung
  • Medizinische Universität Wien
    Verifizierte Postleitzahl
    Wien, Österreich· Rekrutierung
  • Fakultní Nemocnice Olomouc
    Verifizierte Postleitzahl
    Olomouc, Czechia· Noch nicht rekrutiert
  • Všeobecná fakultní nemocnice v Praze
    Verifizierte Postleitzahl
    Prag, Tschechien· Noch nicht rekrutiert
  • Hôpital Bicêtre-- Assistance Publique Hopitaux de Paris
    Verifizierte Postleitzahl
    Paris, Frankreich· Noch nicht rekrutiert
  • Hôpitaux Universitaires de Strasbourg
    Verifizierte Postleitzahl
    Straßburg, Frankreich· Noch nicht rekrutiert
  • DRK Kliniken Berlin Westend
    Verifizierte Postleitzahl
    Berlin, Deutschland· Noch nicht rekrutiert
  • University Hospital Carl Gustav Carus of Technical University Dresden
    Verifizierte Postleitzahl
    Dresden, Deutschland· Noch nicht rekrutiert
  • Universitätsmedizin Greifswald
    Verifizierte Postleitzahl
    Greifswald, Germany· Noch nicht rekrutiert
  • Gottsegen National Cardiovascular lnstitute
    Verifizierte Postleitzahl
    Budapest, Ungarn· Noch nicht rekrutiert
  • Medical University of Szeged
    Verifizierte Postleitzahl
    Szeged, Hungary· Noch nicht rekrutiert
  • Sapienza University of Rome
    Verifizierte Postleitzahl
    Rome, Italy· Rekrutierung

Häufige Fragen

What is PAH?

PAH stands for pulmonary arterial hypertension. It's a condition where the blood pressure in the arteries that carry blood from your heart to your lungs is too high, making your heart work harder.

Welche Art von Medikamenten werden getestet?

The study is testing combinations of medicines. Both groups will get two oral medicines. One group will also get an additional medicine called treprostinil, which is given by injection.

Wie lange wird die Studie für mich dauern?

If you join the study, your treatment and monitoring will last for approximately 6 to 12 months (24 to 48 weeks).

Werde ich wissen, welche Behandlung ich bekomme?

Yes, this is an 'open-label' study, which means both you and your doctor will know whether you are receiving the two oral medicines or the three-medicine combination.

Muss ich bezahlen, um an der Studie teilzunehmen?

No, all study-related treatments and tests are provided at no cost to you.

Wie Sie mehr erfahren können

Clinical Project Manager

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "Initial Triple Therapy Including Parenteral Treprostinil vs … wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.